Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammopharmacology
Published in: Inflammopharmacology 5/2017

01-10-2017 | Original Article

A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease

Authors: Charlotte L. Kvasnovsky, Ingvar Bjarnason, Ana Nora Donaldson, Roy A. Sherwood, Savvas Papagrigoriadis

Published in: Inflammopharmacology | Issue 5/2017

Login to get access

Abstract

Background

Diverticular disease is a significant burden on healthcare systems that is managed, surgically or medically, mainly as an emergency or acute condition. There are no standardized treatment recommendations for symptomatic uncomplicated disease. We hypothesized that a probiotic would reduce abdominal pain in such patients.

Methods

We conducted a single-center, double-blind, placebo-controlled trial of probiotic treatment (Symprove) in adult patients with moderate-to-severe chronic, non-acute symptomatic diverticular disease. 143 patients were randomized to receive 1 mL/kg/day of probiotic liquid (N = 72) or placebo (N = 71) daily for 3 months. The primary endpoint was abdominal pain severity. Secondary endpoints consisted of the change in the frequency of eight abdominal symptoms and the level of intestinal inflammation (fecal calprotectin).

Results

120 patients completed the trial. Abdominal pain score, the primary end point, decreased in both groups, but no significant difference between the groups was found (P = 0.11). In relation to placebo, the probiotic significantly decreased the frequency of four of the eight secondary endpoints: constipation, diarrhea, mucorrhea, and back pain (P < 0.04). No significant differences were found in frequency of abdominal pain, PR bleeding, dysuria, and bloating.

Conclusions

Multi-strain liquid probiotic did not improve abdominal pain scores significantly, but significantly improved the frequency of four other symptoms associated with chronic, non-acute symptomatic diverticular disease.
Literature
Angriman I, Scarpa M, Castagliuolo I (2014) Relationship between pouch microbiota and pouchitis following restorative proctocolectomy for ulcerative colitis. World J Gastroenterol 20:9665–9674CrossRefPubMedPubMedCentral
Boostrom SY, Wolff BG, Cima RR, Merchea A, Dozois EJ, Larson DW (2012) Uncomplicated diverticulitis, more complicated than we thought. J Gastrointest Surg 16:1744–1749CrossRefPubMed
Cohen E, Fuller G, Bolus R, Modi R, Vu M, Shahedi K et al (2013) Increased risk for irritable bowel syndrome after acute diverticulitis. Clin Gastroenterol Hepatol 11:1614–1619CrossRefPubMed
Cuomo R, Barbara G, Andreozzi P, Bassotti GC, Asetti T, Grassini M et al (2013) Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest 43:1147–1155PubMed
Dai C, Jiang M (2012) The incidence and risk factors of post-infectious irritable bowel syndrome: a meta-analysis. Hepatogastroenterology 59:67–72PubMed
Daniels L, Philipszoon LE, Boermeester MA (2014) A hypothesis: important role for gut microbiota in the etiopathogenesis of diverticular disease. Dis Colon Rectum 57:539–543CrossRefPubMed
Hall JF (2014) The microbiome and diverticulitis: a new target for medical therapy? Dis Colon Rectum 57:544–545CrossRefPubMed
Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I (2014) Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol 20:1192–1210CrossRefPubMedPubMedCentral
Humes DJ, Simpson J, Smith J, Sutton P, Zaitoun A, Bush D et al (2012) Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. Neurogastroenterol Motil 24:318-e163CrossRefPubMed
Kvasnovsky CL, Papagrigoriadis S (2015) Symptoms in patients with diverticular disease should not be labelled as IBS. Int J Colorectal Dis 30:995CrossRefPubMed
Kvasnovsky CL, Bjarnason I, Papagrigoriadis S (2015) What colorectal surgeons should know about probiotics: a review. Colorectal Dis 17:840–848CrossRefPubMed
Lahner E, Esposito G, Zullo A, Hassan C, Cannaviello C, Paolo MC et al (2012) High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World J Gastroenterol 18:5918–5924CrossRefPubMedPubMedCentral
Marranzino G, Villena J, Salva S, Alvarez S (2012) Stimulation of macrophages by immunobiotic Lactobacillus strains: influence beyond the intestinal tract. Microbiol Immunol 56(11):771–781CrossRefPubMed
Marshall JK, Thabane M, Borgaonkar MR, James C (2007) Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 5:457–460CrossRefPubMed
Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM, Walkerton Health Study Investigators (2010) Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 59:605–611CrossRefPubMed
Moher D, Schulz KF, Altman DG, CONSORT group (Consolidated Standards of Reporting Trials) (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134:657–662CrossRefPubMed
Morken MH, Lind RA, Valeur J, Wilhelmsen I, Berstad A (2009) Subjective health complaints and quality of life in patients with irritable bowel syndrome following Giardia lamblia infection: a case control study. Scand J Gastroenterol 44:308–313CrossRefPubMed
Neal KR, Hebden J, Spiller R (1997) Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 314:779–782CrossRefPubMedPubMedCentral
Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ et al (2012) Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143:1179–1187CrossRefPubMedPubMedCentral
Schwille-Kiuntke J, Enck P, Zendler C, Krieg M, Polster AV, Klosterhalfen S et al (2011) Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterol Motil 23:479–488CrossRef
Sisson G, Ayis S, Sherwood RA, Bjarnason I (2014) Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome–a 12 week double-blind study. Aliment Pharmacol Ther 40:51–60CrossRefPubMed
Sisson G, Hayee B, Bjarnason I (2015) Assessment of a multi strain probiotic (Symprove) in IBD. Gastroenterology 148:S-531CrossRef
Spiller R (2014) New thoughts on the association between diverticulosis and irritable bowel syndrome. Am J Gastroenterol 109:1906–1908CrossRefPubMed
Tibble JSG, Foster R, Sherwood R, Fagerhol M, Bjarnason I (2001) Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49:402–408CrossRefPubMedPubMedCentral
Tursi A, Brandimarte G, Elisei W, Picchio M, Forti G, Pianese G et al (2013) Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease–a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 38:741–751CrossRefPubMed
Tursi A, Elisei W, Picchio M, Brandimarte G (2014) Increased faecal calprotectin predicts recurrence of colonic diverticulitis. Int J Colorectal Dis 29:931–935CrossRefPubMed
Wolff BG, Boostrom SY (2012) Prophylactic resection, uncomplicated diverticulitis, and recurrent diverticulitis. Dig Dis 30:108–113CrossRefPubMed
Yamada EI, Namori M, Uchida E, Tanida E, Izumi M, Takeshita K et al (2014) Association between the location of diverticular disease and the irritable bowel syndrome: a multicenter study in Japan. Am J Gastroenterol 109:1900–1905CrossRefPubMedPubMedCentral
Metadata
Title
A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease
Authors
Charlotte L. Kvasnovsky
Ingvar Bjarnason
Ana Nora Donaldson
Roy A. Sherwood
Savvas Papagrigoriadis
Publication date
01-10-2017
Publisher
Springer International Publishing
Published in
Inflammopharmacology / Issue 5/2017
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-017-0363-y

Other articles of this Issue 5/2017

Inflammopharmacology 5/2017 Go to the issue

Original Article

Class side effects: decreased pressure in the lower oesophageal and the pyloric sphincters after the administration of dopamine antagonists, neuroleptics, anti-emetics, l-NAME, pentadecapeptide BPC 157 and l-arginine

Original Article

Sodium thiosulphate attenuates brain inflammation induced by systemic lipopolysaccharide administration in C57BL/6J mice

Original Article

Predictive value of salivary microRNA-320a, vascular endothelial growth factor receptor 2, CRP and IL-6 in Oral lichen planus progression

Original Article

Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin–angiotensin system in experimental arthritis

Review

Immunomodulatory basis of antioxidant therapy and its future prospects: an appraisal

Short Communication

Yeast RNA extract suppresses human osteoclast resorption in vitro